Literature DB >> 15463822

Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies.

Niels Høiby1.   

Abstract

Chronic P. aeruginosa infection is characterized by production of mucoid alginate and formation of microcolonies (biofilm) as seen in the lungs of cystic fibrosis patients. Oxygen radicals produced by the inflammatory response polymorphonuclear leucocytes induces the alginate production. The biofilm mode of growth is the survival strategy of environmental bacteria and alginate biofilms are also protected against antibiotics and against the immune response in the lungs of the patient. Quorum sensing is important for early and mature biofilm formation and also for the severity of the infection. The new knowledge of the mechanisms involved in biofilm formation opens up new possibilities for therapeutic intervention strategies involving e.g. inhibitors of quorum sensing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 15463822     DOI: 10.1016/s1569-1993(02)00104-2

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  23 in total

Review 1.  Medical biofilms.

Authors:  James D Bryers
Journal:  Biotechnol Bioeng       Date:  2008-05-01       Impact factor: 4.530

2.  Antimicrobial activity of antisense peptide-peptide nucleic acid conjugates against non-typeable Haemophilus influenzae in planktonic and biofilm forms.

Authors:  Taketo Otsuka; Aimee L Brauer; Charmaine Kirkham; Erin K Sully; Melinda M Pettigrew; Yong Kong; Bruce L Geller; Timothy F Murphy
Journal:  J Antimicrob Chemother       Date:  2016-09-28       Impact factor: 5.790

3.  Amphotericin B is cytotoxic at locally delivered concentrations.

Authors:  Samuel Harmsen; Alex C McLaren; Christine Pauken; Ryan McLemore
Journal:  Clin Orthop Relat Res       Date:  2011-11       Impact factor: 4.176

4.  Novel inhibitors of the Pseudomonas aeruginosa virulence factor LasB: a potential therapeutic approach for the attenuation of virulence mechanisms in pseudomonal infection.

Authors:  George R A Cathcart; Derek Quinn; Brett Greer; Pat Harriott; John F Lynas; Brendan F Gilmore; Brian Walker
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

5.  Pyrimidine Biosynthesis Regulates the Small-Colony Variant and Mucoidy in Pseudomonas aeruginosa through Sigma Factor Competition.

Authors:  Roy Al Ahmar; Brandon D Kirby; Hongwei D Yu
Journal:  J Bacteriol       Date:  2018-12-07       Impact factor: 3.490

6.  LuxR homolog-independent gene regulation by acyl-homoserine lactones in Pseudomonas aeruginosa.

Authors:  Sudha Chugani; Everett Peter Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-24       Impact factor: 11.205

7.  Non-invasive imaging of oxygen concentration in a complex in vitro biofilm infection model using 19 F MRI: Persistence of an oxygen sink despite prolonged antibiotic therapy.

Authors:  Jeffrey W Simkins; Philip S Stewart; Sarah L Codd; Joseph D Seymour
Journal:  Magn Reson Med       Date:  2019-08-02       Impact factor: 4.668

8.  Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms.

Authors:  Timothy D Starner; Joshua D Shrout; Matthew R Parsek; Peter C Appelbaum; GunHee Kim
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

9.  Identification of FleQ from Pseudomonas aeruginosa as a c-di-GMP-responsive transcription factor.

Authors:  Jason W Hickman; Caroline S Harwood
Journal:  Mol Microbiol       Date:  2008-07       Impact factor: 3.501

10.  Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.

Authors:  L F Mandsberg; O Ciofu; N Kirkby; L E Christiansen; H E Poulsen; N Høiby
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.